These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 18611063)

  • 21. Lanthanum carbonate as a first-line phosphate binder: the "cons".
    Drüeke TB
    Semin Dial; 2007; 20(4):329-32. PubMed ID: 17635823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adequate phosphate binding with lanthanum carbonate attenuates arterial calcification in chronic renal failure rats.
    Neven E; Dams G; Postnov A; Chen B; De Clerck N; De Broe ME; D'Haese PC; Persy V
    Nephrol Dial Transplant; 2009 Jun; 24(6):1790-9. PubMed ID: 19144999
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.
    Chiang SS; Chen JB; Yang WC
    Clin Nephrol; 2005 Jun; 63(6):461-70. PubMed ID: 15960148
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lanthanum: new drug. Hyperphosphataemia in dialysis patients: more potential problems than benefits.
    Prescrire Int; 2007 Apr; 16(88):47-50. PubMed ID: 17458039
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of dietary phosphate absorption after single doses of lanthanum carbonate and sevelamer carbonate in healthy volunteers: a balance study.
    Martin P; Wang P; Robinson A; Poole L; Dragone J; Smyth M; Pratt R
    Am J Kidney Dis; 2011 May; 57(5):700-6. PubMed ID: 21354682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lanthanum: a safe phosphate binder.
    Persy VP; Behets GJ; Bervoets AR; De Broe ME; D'Haese PC
    Semin Dial; 2006; 19(3):195-9. PubMed ID: 16689967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phosphate handling in CKD-MBD from stage 3 to dialysis and the three strengths of lanthanum carbonate.
    Cozzolino M; Bruschetta E; Cusi D; Montanari E; Giovenzana ME; Galassi A
    Expert Opin Pharmacother; 2012 Nov; 13(16):2337-53. PubMed ID: 23033914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate.
    Hutchison AJ; Speake M; Al-Baaj F
    Nephrol Dial Transplant; 2004 Jul; 19(7):1902-6. PubMed ID: 15199195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of lanthanum carbonate and calcium carbonate on bone abnormalities in patients with end-stage renal disease.
    Freemont AJ; Hoyland JA; Denton J;
    Clin Nephrol; 2005 Dec; 64(6):428-37. PubMed ID: 16370155
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differences in gastrointestinal calcium absorption after the ingestion of calcium-free phosphate binders.
    Behets GJ; Dams G; Damment SJ; Martin P; De Broe ME; D'Haese PC
    Am J Physiol Renal Physiol; 2014 Jan; 306(1):F61-7. PubMed ID: 24197066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
    Shigematsu T;
    Clin Nephrol; 2008 Nov; 70(5):404-10. PubMed ID: 19000540
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
    Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
    Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study.
    Hutchison AJ; Maes B; Vanwalleghem J; Asmus G; Mohamed E; Schmieder R; Backs W; Jamar R; Vosskühler A
    Nephron Clin Pract; 2006; 102(2):c61-71. PubMed ID: 16224198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Introduction to lanthanum carbonate: pharmacology, safety and tolerability].
    Rodríguez Portillo M
    Nefrologia; 2008; 28 Suppl 5():7-10. PubMed ID: 18847413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Efficacy and safety of lanthanum carbonate in chronic kidney disease patients with hyperphosphataemia].
    Laville M
    Nephrol Ther; 2011 Jun; 7(3):154-61. PubMed ID: 21247818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of effects of lanthanum carbonate with and without phosphate supplementation on bone mineralization in uremic rats.
    Damment SJ; Shen V
    Clin Nephrol; 2005 Feb; 63(2):127-37. PubMed ID: 15730055
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of lanthanum carbonate on cortical bone in dialysis patients with adynamic bone disease.
    Yajima A; Inaba M; Tominaga Y; Tanaka M; Otsubo S; Nitta K; Ito A; Satoh S
    Ther Apher Dial; 2013 Apr; 17 Suppl 1():41-8. PubMed ID: 23586512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Improving outcomes in hyperphosphataemia.
    De Broe ME; D'Haese PC;
    Nephrol Dial Transplant; 2004 Mar; 19 Suppl 1():i14-8. PubMed ID: 15126649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lanthanum carbonate: time to abandon prejudices?
    Brancaccio D; Cozzolino M
    Kidney Int; 2007 Feb; 71(3):190-2. PubMed ID: 17252028
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of lanthanum carbonate on bone markers and bone mineral density in incident hemodialysis patients.
    Goto K; Goto S; Fujii H; Watanabe K; Kono K; Nishi S
    J Bone Miner Metab; 2019 Nov; 37(6):1075-1082. PubMed ID: 31214836
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.